Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$0.93 USD
+0.06 (6.90%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $0.92 -0.01 (-1.08%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
BPTH 0.93 +0.06(6.90%)
Will BPTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BPTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPTH
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
BPTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BPTH
Bio-Path Holdings Announces Publication in Biomedicines
Bio-Path announces publication on BP1003 in Biomedicines
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
Biotech Alert: Searches spiking for these stocks today
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A?s Compelling Potential as Treatment for Advanced Solid Tumors